{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"}],"units":"Participants"}],"description":"Overall survival (OS) is defined as the number of transplant recipients remaining alive at 12 months after transplant. The outcome is expressed as the number of transplant recipients who remained alive at 12 months after treatment, a number without dispersion.","groups":[{"description":"TBI, single exposure on Day -1, 80 centigray (cGy) in addition to total lymphoid irradiation (TLI, 120 cGy/day for 9 days, weekends excluded) and anti-thymocyte globulin (ATG) 1.5 mg/kg (conditioning regimen)\n\nTotal body irradiation (TBI): Administer Total body irradiation (TBI) 80 cGy on Day 1 of standard TLI ATG conditioning\n\nAnti-thymocyte globulin (ATG): Given intravenous (IV), Dose 1.5 mg/kg x 5 days\n\nTacrolimus: Oral, Dose 0.05 mg/kg twice daily, can be given intravenous (IV)\n\nMycophenolate mofetil (MMF): Given Oral, 15 mg/k every 2 hours for peripheral blood stem cells (PBSC) from matched related donors; 15 mg/kg every 8 hours for PBSC from unrelated donors (URDs) or mismatched related donors.\n\nTotal lymphoid irradiation (TLI): 9 x 120 cGy over 11 days","id":"OG000","title":"TBI+TLI"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"1 year","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Participants"}